Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoff Hale

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Biotechnology and Bioengineering|April 2, 2005
Fractionation of bovine serum albumin and monoclonal antibody alemtuzumab using carrier phase ultrafiltrationYinhua Wan, Raja Ghosh, Geoff Hale, et al.
Biotechnology and Bioengineering|April 7, 2005
Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltrationYinhua Wan, Seshadri Vasan, Raja Ghosh, et al.
Analytical Chemistry|March 28, 2017
Ultrafast Separation and Analysis of Monoclonal Antibody Aggregates Using Membrane ChromatographyPedram Madadkar, Umatheny Umatheva, Geoff Hale, et al.
Mabs|September 16, 2024
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptorsGeoff Hale, Jelle De Vos, Alastair Douglas Davy, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 28, 2012
Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometryAlice Harrison, Zhe Liu, Schona Makweche, et al.
Blood|March 16, 2002
Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitutionPhennapha Klangsinsirikul, G Ian Carter, Jennifer L Byrne, et al.
Immunotherapy Advances|December 25, 2025
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritisCatherine A Lawson, Rachel Harry, Bridget Griffiths, et al.
British Journal of Haematology|February 3, 2015
A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplantsLaura Jardine, Amy Publicover, Venetia Bigley, et al.
Plos One|December 21, 2021
Fc-engineered antibodies with immune effector functions completely abolishedIan Wilkinson, Stephen Anderson, Jeremy Fry, et al.
Science Translational Medicine|February 4, 2011
Human CD3 transgenic mice: preclinical testing of antibodies promoting immune toleranceChantal Kuhn, Sylvaine You, Fabrice Valette, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Biotechnology and Bioengineering|April 2, 2005
Fractionation of bovine serum albumin and monoclonal antibody alemtuzumab using carrier phase ultrafiltrationYinhua Wan, Raja Ghosh, Geoff Hale, et al.
Biotechnology and Bioengineering|April 7, 2005
Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltrationYinhua Wan, Seshadri Vasan, Raja Ghosh, et al.
Analytical Chemistry|March 28, 2017
Ultrafast Separation and Analysis of Monoclonal Antibody Aggregates Using Membrane ChromatographyPedram Madadkar, Umatheny Umatheva, Geoff Hale, et al.
Mabs|September 16, 2024
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptorsGeoff Hale, Jelle De Vos, Alastair Douglas Davy, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 28, 2012
Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometryAlice Harrison, Zhe Liu, Schona Makweche, et al.
Blood|March 16, 2002
Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitutionPhennapha Klangsinsirikul, G Ian Carter, Jennifer L Byrne, et al.
Immunotherapy Advances|December 25, 2025
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritisCatherine A Lawson, Rachel Harry, Bridget Griffiths, et al.
British Journal of Haematology|February 3, 2015
A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplantsLaura Jardine, Amy Publicover, Venetia Bigley, et al.
Plos One|December 21, 2021
Fc-engineered antibodies with immune effector functions completely abolishedIan Wilkinson, Stephen Anderson, Jeremy Fry, et al.
Science Translational Medicine|February 4, 2011
Human CD3 transgenic mice: preclinical testing of antibodies promoting immune toleranceChantal Kuhn, Sylvaine You, Fabrice Valette, et al.
Pageof 6